| DOUBEK, Michael a Michal ŠMÍDA. Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? Expert Review of Hematology. ABINGDON: TAYLOR & FRANCIS LTD, 2015, roč. 8, č. 6, s. 743-764. ISSN 1747-4086. doi:10.1586/17474086.2015.1079123. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1318722,
author = {Doubek, Michael and Šmída, Michal},
article_location = {ABINGDON},
article_number = {6},
doi = {http://dx.doi.org/10.1586/17474086.2015.1079123},
keywords = {CD20; CD52; chronic lymphocytic leukemia; monoclonal antibodies; resistance; therapy},
language = {eng},
issn = {1747-4086},
journal = {Expert Review of Hematology},
title = {Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?},
url = {http://www.tandfonline.com/doi/abs/10.1586/17474086.2015.1079123?journalCode=ierr20},
volume = {8},
year = {2015}
}
TY - JOUR
ID - 1318722
AU - Doubek, Michael - Šmída, Michal
PY - 2015
TI - Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?
JF - Expert Review of Hematology
VL - 8
IS - 6
SP - 743-764
EP - 743-764
PB - TAYLOR & FRANCIS LTD
SN - 17474086
KW - CD20
KW - CD52
KW - chronic lymphocytic leukemia
KW - monoclonal antibodies
KW - resistance
KW - therapy
UR - http://www.tandfonline.com/doi/abs/10.1586/17474086.2015.1079123?journalCode=ierr20
L2 - http://www.tandfonline.com/doi/abs/10.1586/17474086.2015.1079123?journalCode=ierr20
N2 - Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and monoclonal antibodies (mAbs) are important part of CLL treatment. The goal of this article was to summarize current literature on the position of mAbs in CLL treatment and to mention factors influencing effectiveness of mAbs in CLL. Several new mAbs have been developed and investigated in CLL over the past few years. Mainly anti-CD20 monoclonal antibodies are still used routinely in CLL therapy. Unfortunately, the clinical application of mAbs needs to be further improved. Novel combinations and sequences of mAbs with other compounds need to be studied in clinical trials in order to increase overall response rate and prolong remission duration. Mechanisms of action of mAbs or mechanisms of resistance to mAbs have to be also investigated to predict effectiveness of mAb in particular patient. 2015 © Informa UK, Ltd.
ER -
DOUBEK, Michael a Michal ŠMÍDA. Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? \textit{Expert Review of Hematology}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2015, roč.~8, č.~6, s.~743-764. ISSN~1747-4086. doi:10.1586/17474086.2015.1079123.
|
